Acute Lymphoblastic Leukemia Version 1.2023
B-Cell Lymphomas Version 4.2023
Biliary Tract Cancers Version 2.2023
Bladder Cancer Version 3.2023
Head and Neck Cancers Version 2.2023
Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 1.2023
Myeloproliferative Neoplasms Version 1.2023
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023
Rectal Cancer Version 3.2023
Systemic Mastocytosis Version 1.2023
Thyroid Carcinoma Version 2.2023
NCCN Guidelines with Evidence Blocks - B-Cell Lymphomas Version 3.2023
NCCN Guidelines with Evidence Blocks - Biliary Tract Cancers Version 2.2023
NCCN Guidelines with Evidence Blocks - Bladder Cancer Version 3.2023
NCCN Guidelines with Evidence Blocks - Head and Neck Cancers Version 2.2023
NCCN Guidelines with Evidence Blocks - Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 1.2023
NCCN Guidelines with Evidence Blocks - Myeloproliferative Neoplasms Version 1.2023
NCCN Guidelines with Evidence Blocks - Rectal Cancer Version 3.2023
NCCN Guidelines with Evidence Blocks - Systemic Mastocytosis Version 1.2023
Colorectal Cancer Screening Version 1.2023
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2023
Lung Cancer Screening Version 2.2023
Antiemesis Version 2.2023
Cancer-Associated Venous Thromboembolic Disease Version 2.2023
Management of Immunotherapy-Related Toxicities Version 2.2023
Smoking Cessation Version 1.2023
Adolescent and Young Adult (AYA) Oncology Version 1.2024